Back to results
US 2020/0368355 A1Published application
Formulations of bendamustine
AssigneeEagle Pharmaceuticals, Inc.
InventorSrikanth Sundaram
Life of this patent
Estimating the term…
Abstract
Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
Claims37
A method of treating chronic lymphocytic leukemia or indolent B cell non-Hodgkin's lymphoma in a subject comprising parenterally administering to the subject a volume of about 100 mL or less of a liquid composition comprising:
- bendamustine;
- a charged cyclopolysaccharide;
- and
- a parenterally acceptable diluent;
- over a period of less than or equal to about 15 minutes.
2 more elements
Dependencies are inferred from the claim text.